Biogen: positive data for Spinraza for infants
(CercleFinance.com) - Biogen has announced, in the Neurometuscular Disorders Review of Data from Nurture, the first study of treatment targeting the cause of spinal muscular atrophy (SMA) in Infants at Pre-symptomatic stages.
According to the biopharmaceutical laboratory, this data demonstrates that beginning Spinraza treatment provides significant results relative to the natural history of the disease.
"As of March 2019, all participants in the study were still alive, without recourse to permanent respiratory assistance and presented a continuous improvement of their condition, including the ability to sit and walk without assistance," the group said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
According to the biopharmaceutical laboratory, this data demonstrates that beginning Spinraza treatment provides significant results relative to the natural history of the disease.
"As of March 2019, all participants in the study were still alive, without recourse to permanent respiratory assistance and presented a continuous improvement of their condition, including the ability to sit and walk without assistance," the group said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.